Moffitt Cancer Center has agreed to a strategic collaboration with AstraZeneca, to accelerate the development of cell therapies, specifically chimeric antigen receptor T cell and T cell receptor therapies.
AstraZeneca will have priority access to Moffitt’s clinical environment and create connections between physician-scientists to advance the investigation of novel cell therapies.
The collaboration aims to address cell therapy development challenges and expand cell therapies’ reach to more patients in the United States and beyond, with a focus on advancing clinical studies to investigate cell therapies in solid tumors and optimizing clinical operations to streamline and expedite the delivery of autologous cell therapies to patients.
